GlassScriptPhysician profile
Mersadies B Orr
NPI 1497232458
$6,191.41
in general payments reported to CMS, 2019-2025
32 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,194 · 2022: $1,341 · 2023: $1,968 · 2024: $1,505 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,349.94 |
| Education | $306.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $863.11 | 2021-2024 | |
| Janssen Biotech, INC. | $737.86 | 2021-2024 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $541.15 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $532.38 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Janssen Scientific Affairs, LLC | $500.00 | 2021 | |
| Dendreon Pharmaceuticals LLC | $384.27 | 2021-2025 | Provenge |
| Eisai INC. | $350.62 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $324.89 | 2022-2024 | Yonsa |
| Astellas Pharma US INC | $306.35 | 2022-2024 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $203.05 | 2022-2024 | Lynparza |
| Genzyme Corporation | $197.20 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $187.98 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $177.19 | 2022-2024 | Opdivo, Krazati |
| Sumitomo Pharma America, INC. | $141.70 | 2023-2024 | Orgovyx |
| Tempus Ai, INC | $99.94 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $96.29 | 2021-2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $79.69 | 2022-2023 | Fotivda |
| Myovant Sciences INC. | $78.76 | 2022 | |
| Myriad Genetic Laboratories, INC. | $53.63 | 2021 | |
| Emd Serono, INC. | $50.13 | 2023 | Bavencio |
| Amgen INC. | $46.43 | 2021 | |
| Progenics Pharmaceuticals, INC. | $39.57 | 2023-2024 | Pylarify |
| Medtronic, INC. | $36.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $29.15 | 2025 | |
| Tolmar, INC. | $21.97 | 2023 | |
| Blue Earth Diagnostics | $21.18 | 2021 | |
| Coherus Oncology, INC. | $17.70 | 2022 | |
| Daiichi Sankyo INC. | $16.32 | 2022 | |
| Caris Mpi, INC. | $15.88 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $14.72 | 2022 | |
| Axonics, INC. | $13.76 | 2023 | Axonics |
| Endo Pharmaceuticals INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mersadies Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.